Tempest Therapeutics (TPST) Competitors $7.36 +0.33 (+4.69%) Closing price 04:00 PM EasternExtended Trading$7.44 +0.07 (+1.02%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST vs. ALTS, TNYA, ATOS, SKYE, HURA, ZURA, SAVA, HLVX, COYA, and CHRSShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include ALT5 Sigma (ALTS), Tenaya Therapeutics (TNYA), Atossa Genetics (ATOS), Skye Bioscience (SKYE), TuHURA Biosciences (HURA), Zura Bio (ZURA), Cassava Sciences (SAVA), HilleVax (HLVX), Coya Therapeutics (COYA), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. Its Competitors ALT5 Sigma Tenaya Therapeutics Atossa Genetics Skye Bioscience TuHURA Biosciences Zura Bio Cassava Sciences HilleVax Coya Therapeutics Coherus Oncology Tempest Therapeutics (NASDAQ:TPST) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment. Do analysts recommend TPST or ALTS? Tempest Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 307.61%. Given Tempest Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tempest Therapeutics is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor TPST or ALTS? In the previous week, Tempest Therapeutics had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 1 mentions for Tempest Therapeutics and 0 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.00 beat Tempest Therapeutics' score of -1.11 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Overall Sentiment Tempest Therapeutics Negative ALT5 Sigma Neutral Do insiders & institutionals have more ownership in TPST or ALTS? 22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by insiders. Comparatively, 4.9% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better valuation and earnings, TPST or ALTS? ALT5 Sigma has higher revenue and earnings than Tempest Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$41.84M-$17.98-0.41ALT5 Sigma$12.53M14.42-$6.24MN/AN/A Which has more risk & volatility, TPST or ALTS? Tempest Therapeutics has a beta of -1.93, suggesting that its share price is 293% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Is TPST or ALTS more profitable? Tempest Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -38.58%. ALT5 Sigma's return on equity of -113.79% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -305.51% -119.74% ALT5 Sigma -38.58%-113.79%-8.96% SummaryALT5 Sigma beats Tempest Therapeutics on 7 of the 13 factors compared between the two stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.09M$2.41B$5.45B$9.68BDividend YieldN/A1.78%3.99%4.14%P/E Ratio-0.4120.1730.1125.01Price / SalesN/A444.85379.5578.79Price / CashN/A165.0335.9458.58Price / Book1.304.128.135.68Net Income-$41.84M$31.61M$3.26B$265.68M7 Day Performance-1.74%0.46%1.15%2.51%1 Month Performance-1.08%2.42%2.81%1.88%1 Year Performance-57.75%4.45%28.41%24.00% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics2.1743 of 5 stars$7.36+4.7%$30.00+307.6%-61.4%$27.09MN/A-0.4120Negative NewsUpcoming EarningsALTSALT5 SigmaN/A$6.81+8.4%N/A+524.4%$109.61M$12.53M0.00170TNYATenaya Therapeutics3.5129 of 5 stars$0.69+3.4%$6.25+801.5%-74.0%$109.08MN/A-0.60110News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastATOSAtossa Genetics2.4112 of 5 stars$0.83+1.3%$6.17+639.7%-33.6%$106.31MN/A-3.978Upcoming EarningsSKYESkye Bioscience1.2435 of 5 stars$3.63+6.5%$16.60+357.3%-31.2%$105.62MN/A0.0011News CoveragePositive NewsEarnings ReportHURATuHURA Biosciences1.2748 of 5 stars$2.59+7.9%$12.67+389.1%N/A$104.83MN/A0.00N/AZURAZura Bio3.7054 of 5 stars$1.46-2.7%$14.33+881.7%-58.1%$102.56MN/A0.003Positive NewsUpcoming EarningsSAVACassava Sciences2.3563 of 5 stars$2.29+8.0%$54.50+2,279.9%-92.7%$102.41MN/A0.0030News CoverageUpcoming EarningsHLVXHilleVax1.9026 of 5 stars$2.07+1.5%$2.00-3.4%+28.0%$102.29MN/A0.0020News CoverageEarnings ReportUpcoming EarningsHigh Trading VolumeCOYACoya Therapeutics2.1576 of 5 stars$6.34+4.1%$16.50+160.3%+2.3%$101.86M$3.55M0.006Upcoming EarningsCHRSCoherus Oncology3.7528 of 5 stars$0.87-1.1%$4.68+439.6%-28.7%$101.77M$266.96M-0.77330News Coverage Related Companies and Tools Related Companies ALTS Alternatives TNYA Alternatives ATOS Alternatives SKYE Alternatives HURA Alternatives ZURA Alternatives SAVA Alternatives HLVX Alternatives COYA Alternatives CHRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TPST) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TPST Stock Alerts